# Allogenic NK Cell Transfusion Azacitidine MDS-EB

> **NCT04599426** · PHASE1,PHASE2 · UNKNOWN · sponsor: **The Second Hospital of Shandong University** · enrollment: 10 (estimated)

## Conditions studied

- MDS-EB

## Interventions

- **BIOLOGICAL:** Allogeneic NK cell regimen group

## Key facts

- **NCT ID:** NCT04599426
- **Lead sponsor:** The Second Hospital of Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-01
- **Primary completion:** 2023-12-30
- **Final completion:** 2023-12-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04599426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04599426, "Allogenic NK Cell Transfusion Azacitidine MDS-EB". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04599426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*